Treatment of epidemic and pandemic influenza with neuraminidase and M2 proton channel inhibitors

Clinical Microbiology and Infection

Volumn 9, Issue 1, 2003, Pages 1-14

  Oxford, J S ^a   Bossuyt, S ^a   Balasingam, S ^a   Mann, A ^a   Novelli, P ^a   Lambkin, R ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Epidemic; Influenza; Inhibitors; M2 proton channel; Neuraminidase; Pandemic

Indexed keywords

ACETYLSALICYLIC ACID; AMANTADINE; INFLUENZA VACCINE; OSELTAMIVIR; PERAMIVIR; PLACEBO; PROTON PUMP INHIBITOR; RIMANTADINE; SIALIDASE; SIALIDASE INHIBITOR; ZANAMIVIR;

ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; BRONCHITIS; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DOSE RESPONSE; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG RESISTANCE; DRUG TARGETING; EPIDEMIC; HIGH RISK POPULATION; HUMAN; INCIDENCE; INFLUENZA; INFLUENZA VIRUS A; INFLUENZA VIRUS B; INSOMNIA; INVESTMENT; MORBIDITY; MORTALITY; NONHUMAN; OTITIS MEDIA; PATIENT CARE; PNEUMONIA; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; SINUSITIS; VERTIGO; VIRUS VIRULENCE;

INFLUENZA VIRUS; INFLUENZAVIRUS A; INFLUENZAVIRUS B;

EID: 0037279614     PISSN: 1198743X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1469-0691.2003.00564.x     Document Type: Review

References (39)

1. Fedson DS, Wajda A, Nicol JP, Hammond GW, Kaiser DL, Roos LL. Clinical effectiveness of influenza vaccination in Manitoba. JAMA 1993; 270: 1956-61.
2. Mulder J, Hers JF. Influenza. Groningen: Wolters-Noordhoff Publishing, 1972.
3. Winternitz MC, Waton IM, McNamara FP. The pathology of influenza. New Haven, CT: Yale University Press, 1920.
4. Stuart-Harris CH, Schild GC, Oxford JS. Influenza, the viruses and the disease. London: Edward Arnold, 1983.
5. Davies WL, Grunert RR, Haff RF et al. Antiviral activity of 1-ada mantanamine (amantadine). Science 1964; 144: 826-63.
6. Hay AJ, Wostenholme Al, Skehel JJ, Smith MH. The molecular basis of the specific anti-influenza action of amantadine. EMBO J 1985; 4: 3021-24.
7. Aoki FY, Sitar DS. Clinical pharmacokinetics of amantadine hydrochloride. Clin Pharmacokinet 1988; 14: 35-51.
8. Oxford JS, Galbraith A. Anti influenza virus activity of amantadine. Viral Chemother 1984; 1: 169-252.
9. Welliver R, Monto AS, Carewicz O et al. Effectiveness of oseltamivir in preventing influenza in household contacts. JAMA 2001; 285: 748-54.
10. Hayden FG, Gubareva LV, Monto AS et al. Inhaled zanamivir for the prevention of influenza in families. N Engl J Med 2000; 343: 778-83.
11. Reuman PD, Bernstein DI, Keefer MC, Moung EC, Sherwood JR, Schiff GM. Efficacy and safety of low dose amantadine hydrochloride as prophylaxis for influenza A. Antiviral Res 1989; 11: 27-40.
12. Oxford JS, Logan LS, Potter CW. In vivo selection of an influenza A2 strain resistant to amantadine. Nature Lond 1970; 226: 82-3.
13. Smorodintsev AA, Zlydnikov DM, Kiseleva AM, Romanov JA, Kazantsev AP, Rumovsky VI. Evaluation of amantadine in artificially induced A2 and B influenza. JAMA 1970; 213(9): 1448-54.
14. Younkin SW, Betts RF, Roth FK, Gordon Douglas R. Reduction in fever in young adults with influenza A/Brazil 78, H1, N1 infection after treatment with aspirin or amantadine. Antimicrob Agents Chemother 1983; 23: 577-82.
15. Sears SD, Clements ML. Protective efficacy of low dose amantadine in adults challenged with wild-type influenza A virus. Antimicrob Agents Chemother 1987; 31(10): 1470-3.
16. Laver WG. Structural studies on the protein subunits from three strains of influenza virus. J Mol Biol 1964; 9: 109.
17. Colman PM, Varghese JN, Laver WG. Structure of the catalytic and antigenic sites in influenza virus neuraminidase. Nature 1983; 303: 41-4.
18. Meindl P, Tuppy H. Uber 2-Desoxy-2,3-de-hydrosialinsauren, II. Kompetitive Hemmung der Vibrio-cholerae-Neuraminidase durch 2-Desoxy-2,3-dehydro-N-acyl-neuraminsauren. [2-Deoxy-2,3-dehydrosialic acids II. Competitive inhibition of Vibrio cholerae neuraminidase by 2-deoxy-2,3-dehydro-N-acylneuramimic acids.] Hoppe Seyler's Z Physiol Chem 1969; 350: 1088-92.
19. Von Itzstein M, Wu WY, Kok GB et al. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 1993; 363: 148-23.
20. Laver WG, Bischofberger N, Webster RG. Disarming flu viruses. Scientific Am 1999; 280: 78-87.
21. Ives JAL, Carr JA, Mendel DB et al. The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo. Antiviral Res 2002; 55: 307-17.
22. Gubareva LV, Kaiser L, Hayden FG. Influenza virus neuraminidase inhibitors. Lancet 2000; 355: 827-35.
23. Mendel DB, Tai CY, Escarpe PA et al. GS 4071 is a potent and selective inhibitor of the growth and neuraminidase activity of influenza A and B virus in vitro. Antiviral Res 1997, 34(2): A73.
24. Brouillette WJ, Atigadda VR, Luo M, Air GM, Babu YS, Bantia S. Design of benzoic acid inhibitors of influenza neuraminidase containing a cyclic substitution for the N-acetyl grouping. Bioorganic Med Cem Lett 1999; 9(14): 1901-6.
25. Luo M, Air GM, Brouillette WJ. Design of aromatic inhibitors of influenza virus neuraminidase. J Infect Dis 1997; 176(suppl 1): S62-5.
26. Kim CU, Lew W, Williams MA et al. Structure-activity relationship studies of novel carbocyclic influenza neuraminidase inhibitors. J Med Chem 1998; 41(14): 2451-60.
27. Hayden FG, Treanor JJ, Betts RF, Lobo M, Esinhart JD, Hussey EK. Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza. JAMA 1996; 275(4): 24-31.
28. Hayden FG, Osterhaus AD, Treanor JJ. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza virus infections. N Engl J Med 1997; 337: 874-80.
29. Makela MJ, Pauksens K, Rostila T et al. Clinical efficacy and safety of the orally inhaled neuraminidase inhibitor zanamivir in the treatment of influenza: a randomised, double-blind, placebo-controlled European study. I Infect 2000; 40: 42-8.
30. Monto AS, Fleming DM, Henry D et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza A and B virus infections. J Infect Dis 1999; 180: 254-61.
31. Oxford JS, Lambkin R. Targeting influenza virus neuraminidase - a new strategy for antiviral therapy. Drug Discovery Today 1998; 3(10): 448-56.
32. Nicholson KG, Aoki FY, Osterhaus ADME et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Lancet 2000; 355: 1845-50.
33. Treanor JJ, Hayden FG, Vrooman PS et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza. JAMA 2000; 283: 1016-24.
34. Oxford JS, Osterhaus A, Lavanchy D. Influenza: a race against time. Brussels: Roche & Retroscreen Focus Document, 2001.
35. Public Health Laboratory Service. Response to a pandemic of influenza: an action plan. PHLS Digest 1993; 10: 147-54.
36. Oxford JS. Influenza A pandemics of the 20th century with special reference to 1918: virology, pathology and epidemiology. Rev Med Virol 2000; 10: 119-33.
37. Meltzer MI, Cox NJ, Fukuda K. The economic impact of pandemic influenza in the United States: priorities for intervention. Emerg Infect Dis 1999; 5: 659-71.
38. Reid AH, Fanning TG, Hultin JV, Taubenberger JK. Origin and evolution of the 1918 Spanish influenza virus haemagglutinin gene. Proc Natl Acad Sci USA 1999; 96: 1651-6.
39. Davis LJ, Heginbottom AJ, Annan PA et al. Ground penetrating radar survey to locate 1918 Spanish flu victims in permafrost. J Forensic Sci 2000; 20: 68-76.